Patents by Inventor Craig Fox
Craig Fox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9078885Abstract: A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles.Type: GrantFiled: April 7, 2014Date of Patent: July 14, 2015Assignee: Pulmagen Therapeutics (Inflammation) LimitedInventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bondil Van Niel, Andrew Forrest
-
Publication number: 20150110423Abstract: An embodiment includes a bag comprising mesh and film side walls and a reinforcing strip of film; wherein (a) the mesh side wall is sealed to opposing side edges of the film side wall; (b) the reinforcing strip of film is sealed to an upper portion of the mesh side wall and to the opposing side edges of the film side wall; (c) the film side wall has a bottom extension, which is monolithic with the film side wall, extending upwardly and sealed along a lateral extent of a bottom portion of the mesh side wall; (d) the film side wall is non-coplanar with a portion of the bottom extension; (e) another portion of the bottom extension is non-coplanar with the mesh side wall; and (f) a horizontal axis intersects the bottom portion of the film side wall and three portions of the bottom extension.Type: ApplicationFiled: October 16, 2014Publication date: April 23, 2015Inventors: L. Keith Fox, Aaron Fox, Craig Fox
-
Publication number: 20140248357Abstract: A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles.Type: ApplicationFiled: April 7, 2014Publication date: September 4, 2014Applicant: PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITEDInventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bondil Van Niel, Andrew Forrest
-
Patent number: 8815837Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.Type: GrantFiled: June 29, 2012Date of Patent: August 26, 2014Assignee: Pulmagen Therapeutics (Inflammation) LimitedInventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bondil Van Niel, Andrew Forrest
-
Publication number: 20130309227Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: June 18, 2013Publication date: November 21, 2013Applicant: Domantis LimitedInventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Greogory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8497244Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: January 23, 2012Date of Patent: July 30, 2013Assignee: Domantis LimitedInventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8431553Abstract: There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.Type: GrantFiled: February 13, 2006Date of Patent: April 30, 2013Assignee: Pulmagen Therapeutics (Synergy) LimitedInventors: Justian Craig Fox, Mary Frances Fitzgerald, Harry Finch
-
Patent number: 8426393Abstract: There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.Type: GrantFiled: August 24, 2010Date of Patent: April 23, 2013Assignee: Pulmagen Therapeutics (Synergy) LimitedInventors: Justian Craig Fox, Mary Frances Fitzgerald, Harry Finch
-
Patent number: 8362064Abstract: Compounds of formula (I) are agonists of PPAR?, useful for the treatment of respiratory disease; formula (I): wherein R1, R2 or R3 each independently represents halo, cyano, nitro, amino, alkyl, haloalkyl, alkoxy, haloalkoxy, carboxylic acid or an ester or amide thereof; R4 represents hydrogen or alkyl; m, n or p independently represents 0, 1, 2 or 3.Type: GrantFiled: December 23, 2009Date of Patent: January 29, 2013Assignee: Pulmagen Theraputics (Inflammation) LimitedInventors: Vidya Ramdas, Harry Finch, Craig Fox
-
Publication number: 20120264787Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.Type: ApplicationFiled: June 29, 2012Publication date: October 18, 2012Applicant: Pulmagen Therapeutics (Inflammation) LimitedInventors: Harry FINCH, Craig FOX, Mohammed SAJAD, Monique Bodil VAN NIEL, Andrew FORREST
-
Patent number: 8236786Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.Type: GrantFiled: August 4, 2010Date of Patent: August 7, 2012Assignee: Pulmagen Therapeutics (Inflammation) LimitedInventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bodil Van Niel, Andrew Forrest
-
Publication number: 20120114651Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: January 23, 2012Publication date: May 10, 2012Inventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Patent number: 8129503Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: GrantFiled: October 23, 2006Date of Patent: March 6, 2012Assignee: Domantis LimitedInventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20120041043Abstract: Compounds of formula (I) are agonists of PPAR?, useful for the treatment of respiratory disease; formula (I): wherein R1, R2 or R3 each independently represents halo, cyano, nitro, amino, alkyl, haloalkyl, alkoxy, haloalkoxy, carboxylic acid or an ester or amide thereof; R4 represents hydrogen or alkyl; m, n or p independently represents 0, 1, 2 or 3.Type: ApplicationFiled: December 23, 2009Publication date: February 16, 2012Applicants: Pulmagen Therapeutics (Inflammation) Limited, Dr. Reddy's Laboratories LTDInventors: Vidya Ramdas, Harry Finch, Craig Fox
-
Publication number: 20110053986Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.Type: ApplicationFiled: August 4, 2010Publication date: March 3, 2011Inventors: Harry Finch, Craig Fox, Mohammed Sajad, Monique Bodil Van Niel, Andrew Forrest
-
Publication number: 20100324002Abstract: There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.Type: ApplicationFiled: August 24, 2010Publication date: December 23, 2010Inventors: Justian Craig Fox, Mary Frances Fitzgerald, Harry Finch
-
Publication number: 20100034831Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.Type: ApplicationFiled: October 23, 2006Publication date: February 11, 2010Inventors: Rudolf M.T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
-
Publication number: 20090199080Abstract: An adaptation system adapts a web page, which is developed to be displayed by a web browser, to be displayed by client-side code of an application. When a web server receives a request for a web page, it determines whether the request was sent from a client device executing client-side code or from a non-client device executing a browser. If the request is from a client, then the web server uses the adaptation system to adapt the web page to the environment of the application. The adaptation system may modify the web page so that the menus of the web page are not displayed when the web page is displayed within a window of the application. The adaptation system may also modify links of the content of the web page to reference forms of the application, rather than other web pages.Type: ApplicationFiled: January 31, 2008Publication date: August 6, 2009Applicant: Microsoft CorporationInventors: Craig Fox, Meyyappan Meenakshisundaram, Hitesh Jawa, Chad Waldman
-
Publication number: 20090191217Abstract: Disclosed is the use of an antagonist of Interleukin 1 receptor type 1 (IL-1R1) for the manufacture of a medicament treating, preventing or suppressing lung inflammation or a respiratory disease. In some embodiments of the described invention, the medicament is for local administration to pulmonary tissue. Also disclosed are methods for treating lung inflammation or a respiratory disease.Type: ApplicationFiled: December 1, 2005Publication date: July 30, 2009Inventors: Ruud M. de Wildt, Philip D. Drew, Ian M. Tomlinson, Mary Fitzgerald, Craig Fox, Steve Holmes
-
Publication number: 20080318912Abstract: There is provided the use of a methylxanthine compound and a steroid in a synergistic combination for the treatment of a respiratory disease, wherein the methylxanthine compound is administered at a dose, which, in isolation, is not effective to treat said disease.Type: ApplicationFiled: August 3, 2005Publication date: December 25, 2008Inventors: Craig Fox, Harry Finch, Mary Fitzgerald